Stock Analysis
- United States
- /
- Biotech
- /
- NasdaqGS:SRPT
Nvidia And 2 Other High Growth Tech Stocks In The United States
Reviewed by Simply Wall St
Over the last 7 days, the United States market has remained flat, yet it is up 22% over the past year with earnings expected to grow by 15% per annum in the coming years. In this context of steady growth and promising future earnings, identifying high-growth tech stocks like Nvidia can be crucial for investors seeking to capitalize on technological advancements and innovation-driven sectors.
Top 10 High Growth Tech Companies In The United States
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 24.36% | 24.28% | ★★★★★★ |
Ardelyx | 21.09% | 55.29% | ★★★★★★ |
AVITA Medical | 33.20% | 51.87% | ★★★★★★ |
Bitdeer Technologies Group | 51.56% | 122.57% | ★★★★★★ |
TG Therapeutics | 29.48% | 43.58% | ★★★★★★ |
Alkami Technology | 21.99% | 102.65% | ★★★★★★ |
Clene | 61.16% | 59.11% | ★★★★★★ |
Alnylam Pharmaceuticals | 21.62% | 56.70% | ★★★★★★ |
Blueprint Medicines | 23.52% | 55.88% | ★★★★★★ |
Travere Therapeutics | 30.52% | 61.89% | ★★★★★★ |
Click here to see the full list of 234 stocks from our US High Growth Tech and AI Stocks screener.
Let's uncover some gems from our specialized screener.
Sarepta Therapeutics (NasdaqGS:SRPT)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in RNA-targeted therapeutics and gene therapies for rare diseases, with a market cap of $10.90 billion.
Operations: Sarepta focuses on discovering, developing, manufacturing, and delivering therapies for rare diseases, generating $1.64 billion in revenue from these activities.
Sarepta Therapeutics has demonstrated a robust trajectory in the biotech sector, with an annual revenue growth rate of 17.8% and earnings expected to surge by 29.9% annually. Notably, its commitment to innovation is underscored by substantial R&D investments, which are pivotal in driving forward its gene therapy solutions such as ELEVIDYS for Duchenne muscular dystrophy—a treatment that recently showcased positive Phase 3 results. These developments not only enhance Sarepta's market position but also signify potential long-term impacts on the treatment landscape for genetic disorders, reflecting both immediate gains and strategic depth in its pipeline.
- Delve into the full analysis health report here for a deeper understanding of Sarepta Therapeutics.
Explore historical data to track Sarepta Therapeutics' performance over time in our Past section.
Cloudflare (NYSE:NET)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Cloudflare, Inc. is a cloud services provider offering various solutions to businesses globally, with a market capitalization of approximately $48.10 billion.
Operations: The company generates revenue primarily from its Internet Telephone segment, amounting to $1.57 billion.
Amidst a dynamic tech landscape, Cloudflare stands out with its innovative strides in digital content authenticity. Recently unveiling a one-click solution for content credentials, this feature not only enhances the integrity of digital media but also positions Cloudflare as a pioneer in combating AI-generated misinformation. With an 18.4% annual revenue growth and upcoming profitability, marked by an expected earnings growth of 32.2% per year, the company's R&D commitment is evident as it capitalizes on trends like increased demand for secure and verifiable online content. This strategic focus not only addresses immediate market needs but also solidifies its role in shaping future digital standards globally.
Pure Storage (NYSE:PSTG)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Pure Storage, Inc. provides data storage and management technologies, products, and services both in the United States and internationally, with a market cap of approximately $22.30 billion.
Operations: Pure Storage generates revenue primarily from its computer storage devices, with reported sales of $3.08 billion.
Amid the competitive landscape of high-capacity data storage solutions, Pure Storage's strategic alliance with Micron Technology underscores its commitment to innovation and efficiency. The partnership, leveraging Micron's G9 QLC NAND technology, aims to enhance the performance and energy efficiency of Pure Storage’s DirectFlash Modules. This collaboration not only boosts storage density and reduces latency but also aligns with modern data centers' needs for sustainable and scalable solutions. With a recent revenue report showing a growth to $831.07 million in Q3 2024 from $762.84 million in the previous year, alongside a net income increase to $63.64 million from $70.39 million, Pure Storage is positioning itself as a pivotal player in addressing the exponential growth demands of digital storage while maintaining robust financial health.
- Dive into the specifics of Pure Storage here with our thorough health report.
Review our historical performance report to gain insights into Pure Storage's's past performance.
Make It Happen
- Investigate our full lineup of 234 US High Growth Tech and AI Stocks right here.
- Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
- Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:SRPT
Sarepta Therapeutics
A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.